2021

Professional development Vacancies
2021
Regarding amendments to the instructions for medical use of medicinal products containing perindopril (perindopril)

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing…

Read more
Regarding amendments to the package inserts for medical use of medicinal products containing baclofen [for oral use]

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing…

Read more
The benefit of medicinal products containing ifosfamide in the form of a solution for infusion continues to outweigh the risks

The previous decision on this topic has already been covered by the European Medicines Agency (EMA) and posted on the website of the State Expert Center of the Ministry of Health…

Read more
The Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA): conducted a study of the process of detecting NDMA impurities in medicinal products containing ranitidine

The Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) conducted…

Read more
Safety update on the vaccine against COVID-19 VAXZEVRIA AstraZeneca AB

On July 14, 2021, the Pharmacovigilance Risk Assessment Committee (PRAC) published an update of safety information on the COVID-19 vaccine VAXZEVRIA AstraZeneca…

Read more
VigiBase database signal from the Uppsala Monitoring Centre: myocarditis and vaccines against COVID-19

Information on the risk of myocarditis and pericarditis following the use of COVID-19 vaccines according to the Ministry of Health of Canada (Health Canada)…

Read more
Signal from the VigiBase database of the Uppsala Monitoring Centre: Moderna COVID-19 vaccine and delayed local adverse reactions

On March 1, 2021, during a cluster analysis of individual safety reports in the WHO global database VigiBase, two clusters were identified…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing tofacitinib (tofacitinib)

Having reviewed the data of the post-marketing study A3921133 submitted by the registration certificate holder (RCH), the PRAC agreed that the RCH of the medicinal product XELJANZ (Pfizer) must…

Read more
On amendments to the instructions for medical use of medicinal products containing tobramycin (tobramycin) [for systemic use]

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing…

Read more
The European Medicines Agency (EMA) is starting a review of the safety and efficacy of the medicinal product STRESAM® (etifoxine), used for manifestations of anxiety

EMA has begun a review of the safety and efficacy of the medicinal product STRESAM® (etifoxine). When analyzing available safety data on the medicinal product STRESAM® (including…

Read more